Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40-70 years of age. (Q50945932)

From Wikidata

Jump to navigation Jump to search

scientific article published on 30 May 2013

Language	Label	Description	Also known as
English	Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40-70 years of age.	scientific article published on 30 May 2013

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23727002

Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40-70 years of age. (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23727002

toll-like receptor

0 references

0 references

1 reference

based on heuristic

inferred from title

Hepatitis B vaccine

1 reference

based on heuristic

inferred from title

author name string

William L Heyward

1

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23727002

Michael Kyle

2

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23727002

Joseph Blumenau

3

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23727002

Matthew Davis

4

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23727002

Keith Reisinger

5

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23727002

Martin L Kabongo

6

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23727002

Sean Bennett

7

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23727002

Robert S Janssen

8

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23727002

Hamid Namini

9

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23727002

J Tyler Martin

10

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23727002

language of work or name

0 references

publication date

30 May 2013

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23727002

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23727002

31

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23727002

46

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23727002

5300-5305

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23727002

Immunization against hepatitis B--what can we expect? Results of a survey of antibody response to immunization in persons 'at risk' of occupational exposure to hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.068

7 January 2021

A prospective study of in vitro anti-HBs producing B cells (spot-ELISA) following primary and supplementary vaccination with a recombinant hepatitis B vaccine in insulin dependent diabetic patients and matched controls

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.068

7 January 2021

Immunogenicity of combined hepatitis A and B vaccine in elderly persons

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.068

7 January 2021

Hepatitis B vaccine responsiveness in Connecticut public safety personnel

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.068

7 January 2021

Hepatitis B Vaccination in Diabetic Patients: Randomized trial comparing recombinant vaccines containing and not containing pre-S2 antigen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.068

7 January 2021

Immunogenicity of hepatitis B Vaccines. Implications for persons at occupational risk of hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.068

7 January 2021

Antibody-response to three recombinant hepatitis B vaccines: comparative evaluation of multicenter travel-clinic based experience

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.068

7 January 2021

The effect of age on immunologic response to recombinant hepatitis B vaccine: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.068

7 January 2021

Hepatitis A/B vaccination of adults over 40 years old: comparison of three vaccine regimens and effect of influencing factors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.068

7 January 2021

Evaluation of hepatitis B vaccine immunogenicity among older adults during an outbreak response in assisted living facilities

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.068

7 January 2021

Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in health

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.068

7 January 2021

Safety and immunogenicity of different two-dose regimens of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide) in healthy young adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.068

7 January 2021

Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.068

7 January 2021

The prevention of hepatitis B with vaccine. Report of the centers for disease control multi-center efficacy trial among homosexual men

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.068

7 January 2021

What level of hepatitis B antibody is protective?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.068

7 January 2021

Compliance with multiple-dose vaccine schedules among older children, adolescents, and adults: results from a vaccine safety datalink study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.068

7 January 2021

THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.068

7 January 2021

Identifiers

10.1016/J.VACCINE.2013.05.068

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23727002

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23727002

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50945932&oldid=1566766815"